PAM Stock Recent News

PAM LATEST HEADLINES

PAM Stock News Image - zacks.com

PAM makes a strong case for investment, given its growth prospects, strong ROE, debt management and focus on clean power generation.

zacks.com 2024 Oct 18
PAM Stock News Image - zacks.com

We have screened bargain stocks PAM, NOMD, KBH, COLB and SLGN based on the EV-to-EBITDA ratio, which gives the true picture of valuation and earnings potential.

zacks.com 2024 Oct 18
PAM Stock News Image - zacks.com

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

zacks.com 2024 Oct 16
PAM Stock News Image - globenewswire.com

Partnership aims to help businesses eliminate vulnerable attack surfaces and provide a more streamlined user experience. SAN FRANCISCO, Oct. 08, 2024 (GLOBE NEWSWIRE) -- Badge Inc.

globenewswire.com 2024 Oct 08
PAM Stock News Image - zacks.com

PAM, STRL, and ATAT made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on September 30, 2024.

zacks.com 2024 Sep 30
PAM Stock News Image - zacks.com

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

zacks.com 2024 Sep 30
PAM Stock News Image - zacks.com

MRX, ANGO, OPRA, ATAT and PAM have been added to the Zacks Rank #1 (Strong Buy) List on September 30, 2024.

zacks.com 2024 Sep 30
PAM Stock News Image - zacks.com

OPRA, PAM, and SIRI made it to the Zacks Rank #1 (Strong Buy) value stocks list on September 30, 2024.

zacks.com 2024 Sep 30
PAM Stock News Image - globenewswire.com

Launched Neurosterix with Perceptive Advisors to accelerate the development of M4PAM for schizophrenia Indivior selected GABA B PAM drug candidate for development in substance use disorders Addex selected independent GABAB PAM drug candidate for development in chronic cough Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, September 30, 2024 - Addex Therapeutics (SIX/NASDAQ: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders, today reported its half-year and second quarter financial results for the periods ended June 30, 2024, and provided a corporate update.

globenewswire.com 2024 Sep 30
PAM Stock News Image - zacks.com

PAM, UI and BPRN made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on September 19, 2024.

zacks.com 2024 Sep 19
10 of 50